Several outlets report that the U.S. Food and Drug Administration (FDA) is moving away from formal rulemaking and toward prominent media announcements, citing actions associated with Health Secretary Robert F. Kennedy Jr. and FDA Commissioner Marty Makary. MedPage Today describes one of Kennedy Jr.’s early major initiatives: a news conference announcing a plan to “phase out” synthetic food dyes. Other coverage characterizes the overall approach as emphasizing public-facing announcements of policy changes before corresponding regulatory text is drafted.
The Independent frames this pattern as “lots of media announcements but not much rulemaking,” noting that officials repeatedly describe major changes prior to the development of new rules. Courthouse News similarly highlights the lack of resistance from regulated companies, suggesting that industry has not broadly challenged the approach even as the agency’s formal regulatory activity appears limited.
Together, the reporting portrays a communications-led strategy within the FDA and related leadership, with the key criticism centered on the timing and extent of formal rulemaking compared with announcement-driven policy initiatives.
